Literature DB >> 23525048

Correction: liang, j., et Al. Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and e-cadherin. Int. J. Mol. Sci. 2012, 13, 10594-10607.

Dong Chen1, Yan Wang, Kejun Zhang, Xuelong Jiao, Bomin Yan, Jun Liang.   

Abstract

The original version of the paper reports that "OGX-011 is a second generation 21-mer oligonucleotide with a 20-O-(2-methoxy)-ethyl modification, generously provided by OncoGenex Technologies (OncoGenex, Vancouver, Canada)" [1] (p. 10602). OGX-011 was not provided by OncoGenex Technologies directly. Therefore, we would like to correct the wording to: "OGX-011 was obtained without the benefit of an agreement with OncoGenex, or The University British Columbia, or any other party". The authors would like to apologize for any inconvenience this may have caused to the readers of this journal.

Entities:  

Year:  2013        PMID: 23525048      PMCID: PMC3634411          DOI: 10.3390/ijms14036516

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


The original version of the paper reports that “OGX-011 is a second generation 21-mer oligonucleotide with a 20-O-(2-methoxy)-ethyl modification, generously provided by OncoGenex Technologies (OncoGenex, Vancouver, Canada)” [1] (p. 10602). OGX-011 was not provided by OncoGenex Technologies directly. Therefore, we would like to correct the wording to: “OGX-011 was obtained without the benefit of an agreement with OncoGenex, or The University British Columbia, or any other party”. The authors would like to apologize for any inconvenience this may have caused to the readers of this journal.
  1 in total

1.  Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin.

Authors:  Dong Chen; Yan Wang; Kejun Zhang; Xuelong Jiao; Bomin Yan; Jun Liang
Journal:  Int J Mol Sci       Date:  2012-08-23       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.